163 related articles for article (PubMed ID: 14636465)
1. [The effect of proton pump inhibitor on intragastric acidity and it relation to S-mephenytoin hydroxylase genetic polymorphism].
Wang H; Nie YQ; Dai SJ; She QZ; Li YY
Zhonghua Nei Ke Za Zhi; 2003 Nov; 42(11):777-80. PubMed ID: 14636465
[TBL] [Abstract][Full Text] [Related]
2. Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers.
Saitoh T; Fukushima Y; Otsuka H; Hirakawa J; Mori H; Asano T; Ishikawa T; Katsube T; Ogawa K; Ohkawa S
Aliment Pharmacol Ther; 2002 Oct; 16(10):1811-7. PubMed ID: 12269976
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotype in healthy Chinese subjects.
Hu YM; Xu JM; Mei Q; Xu XH; Xu SY
Acta Pharmacol Sin; 2005 Mar; 26(3):384-8. PubMed ID: 15715938
[TBL] [Abstract][Full Text] [Related]
4. CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole.
Adachi K; Katsube T; Kawamura A; Takashima T; Yuki M; Amano K; Ishihara S; Fukuda R; Watanabe M; Kinoshita Y
Aliment Pharmacol Ther; 2000 Oct; 14(10):1259-66. PubMed ID: 11012469
[TBL] [Abstract][Full Text] [Related]
5. Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem.
Klotz U
Int J Clin Pharmacol Ther; 2006 Jul; 44(7):297-302. PubMed ID: 16961157
[TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamic and kinetic effect of rabeprazole on serum gastrin level in relation to CYP2C19 polymorphism in Chinese Hans.
Hu YM; Mei Q; Xu XH; Hu XP; Hu NZ; Xu JM
World J Gastroenterol; 2006 Aug; 12(29):4750-3. PubMed ID: 16937451
[TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes.
Horai Y; Kimura M; Furuie H; Matsuguma K; Irie S; Koga Y; Nagahama T; Murakami M; Matsui T; Yao T; Urae A; Ishizaki T
Aliment Pharmacol Ther; 2001 Jun; 15(6):793-803. PubMed ID: 11380317
[TBL] [Abstract][Full Text] [Related]
8. Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status.
Sugimoto M; Furuta T; Shirai N; Kajimura M; Hishida A; Sakurai M; Ohashi K; Ishizaki T
Clin Pharmacol Ther; 2004 Oct; 76(4):290-301. PubMed ID: 15470328
[TBL] [Abstract][Full Text] [Related]
9. Acid-suppressive effects of rabeprazole, omeprazole, and lansoprazole at reduced and standard doses: a crossover comparative study in homozygous extensive metabolizers of cytochrome P450 2C19.
Shimatani T; Inoue M; Kuroiwa T; Xu J; Mieno H; Nakamura M; Tazuma S
Clin Pharmacol Ther; 2006 Jan; 79(1):144-52. PubMed ID: 16413249
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the effect on intragastric pH of a single dose of omeprazole or rabeprazole: which is suitable for on-demand therapy?
Inamori M; Togawa J; Takahashi K; Yoneda M; Fujisawa N; Iwasaki T; Ozawa Y; Kikuchi T; Muramatsu K; Chiguchi G; Matsumoto S; Kawamura H; Abe Y; Kirikoshi H; Kobayashi N; Sakaguchi T; Takamura T; Nakajima A; Ueno N; Sekihara H
J Gastroenterol Hepatol; 2003 Sep; 18(9):1034-8. PubMed ID: 12911659
[TBL] [Abstract][Full Text] [Related]
11. Rabeprazole experience in Korea; focus on CYP2C19 polymorphism.
Park SH
J Gastroenterol Hepatol; 2005 Dec; 20 Suppl():S20-1. PubMed ID: 16359345
[No Abstract] [Full Text] [Related]
12. Review article: relationship between the metabolism and efficacy of proton pump inhibitors--focus on rabeprazole.
Horn J
Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 6():11-9. PubMed ID: 15496214
[TBL] [Abstract][Full Text] [Related]
13. Effect of lansoprazole and rabeprazole on tacrolimus pharmacokinetics in healthy volunteers with CYP2C19 mutations.
Itagaki F; Homma M; Yuzawa K; Nishimura M; Naito S; Ueda N; Ohkohchi N; Kohda Y
J Pharm Pharmacol; 2004 Aug; 56(8):1055-9. PubMed ID: 15285851
[TBL] [Abstract][Full Text] [Related]
14. Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH.
Shirai N; Furuta T; Moriyama Y; Okochi H; Kobayashi K; Takashima M; Xiao F; Kosuge K; Nakagawa K; Hanai H; Chiba K; Ohashi K; Ishizaki T
Aliment Pharmacol Ther; 2001 Dec; 15(12):1929-37. PubMed ID: 11736724
[TBL] [Abstract][Full Text] [Related]
15. Comparison of an increased dosage regimen of rabeprazole versus a concomitant dosage regimen of famotidine with rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotypes.
Sugimoto M; Furuta T; Shirai N; Nakamura A; Kajimura M; Hishida A; Ohashi K; Ishizaki T
Clin Pharmacol Ther; 2005 Apr; 77(4):302-11. PubMed ID: 15903128
[TBL] [Abstract][Full Text] [Related]
16. A comparative study on endoscopic ulcer healing of omeprazole versus rabeprazole with respect to CYP2C19 genotypic differences.
Ando T; Kato H; Sugimoto N; Nagao Y; Seto N; Hongo H; Kajikawa H; Isozaki Y; Shimozawa M; Naito Y; Yoshida N; Ishizaki T; Yoshikawa T
Dig Dis Sci; 2005 Sep; 50(9):1625-31. PubMed ID: 16133961
[TBL] [Abstract][Full Text] [Related]
17. [Comparative effectiveness of the antisecretory action of rabeprazole and esomeprazole in people with rapid metabolism of proton pump inhibitors].
Morozov SV; Tsodikova OM; Isakov VA; Gushchin AE; Shipulin GA
Eksp Klin Gastroenterol; 2003; (6):58-63, 154. PubMed ID: 15065530
[TBL] [Abstract][Full Text] [Related]
18. Effect of a single oral dose of rabeprazole on nocturnal acid breakthrough and nocturnal alkaline amplitude.
Luo JY; Niu CY; Wang XQ; Zhu YL; Gong J
World J Gastroenterol; 2003 Nov; 9(11):2583-6. PubMed ID: 14606102
[TBL] [Abstract][Full Text] [Related]
19. Comparison of lansoprazole and famotidine for gastric acid inhibition during the daytime and night-time in different CYP2C19 genotype groups.
Shirai N; Furuta T; Xiao F; Kajimura M; Hanai H; Ohashi K; Ishizaki T
Aliment Pharmacol Ther; 2002 Apr; 16(4):837-46. PubMed ID: 11929404
[TBL] [Abstract][Full Text] [Related]
20. Effects of different omeprazole dosing on gastric pH in non-variceal upper gastrointestinal bleeding: A randomized prospective study.
Chwiesko A; Charkiewicz R; Niklinski J; Luczaj W; Skrzydlewska E; Milewski R; Baniukiewicz A; Wroblewski E; Rosolowski M; Dabrowski A
J Dig Dis; 2016 Sep; 17(9):588-599. PubMed ID: 27518195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
